Therapeutic application of anti-growth factor receptor antibodies

Current Opinion in Oncology

Volumn 10, Issue 1, 1998, Pages 67-73

  Fan, Zhen ^a   Mendelsohn, John ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 225; MONOCLONAL ANTIBODY 4D5; MONOCLONAL ANTIBODY 528; PACLITAXEL; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG TARGETING; ENDOCYTOSIS; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0031974705     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199801000-00011     Document Type: Review

References (58)

1. Mendelsohn J, Baselga J: Antibodies to growth factors and receptors. In Biologic Therapy of Cancer, edn 2. Edited by DeVita AP Jr, Hellman S, Rosenberg SA. Philadelphia: JB Lippincott; 1995:607-623.
2. Divgi CR, Welt C, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, et al.: Phase I and imaging trial of indium-111 1abeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991, 83:97-104.
3. 125I-labeled monoclonal antibody against epidermal growth factor receptor. Antibody Immun Radiopharm 1990, 3:169-179.
4. Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang H-Z, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK, et al.: Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG83852. J Clin Oncol 1994, 12:730-739.
5. Kalofonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavendar PJ: Antibody guided diagnosis and therapy of brain gliomas using radio-labeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989, 30:1636-1645.
6. Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spenser L, et al.: Phase I trial and tumor localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996, 73:228-235.
7. Reust CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR: Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 1997, 57:1510-1515.
8. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318.
9. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher H, Goldstein NI: The biological effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother 1996, 19:419-427.
10. Bos M, Mendelsohn J, Bowden C, Pfister D, Cooper MR, Cohen R, Burtness B, D'Andrea G, Waksal H, Norton L, et al.: Phase I studies of anti-epidermal growth factor receptor chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors [abstract 1381]. Proc Am Soc Clin Oncol 1996, 15:443.
11. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER-2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744.
12. Kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996, 12:1397-1403.
13. Kip1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996, 56:3666-3669.
14. Cip1 in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 1997, 3:1943-1948.
15. Chou JL, Fan Z, Koff A, Mendelsohn J: EGF receptor blockage induces reversible growth arrest and changes in proteins that regulate the cell cycle in human mammary epithelial cells [abstract 68]. Proc Am Assoc Cancer Res 1996, 37:10.
16. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J: Apoptosis induced by an anti-EGF receptor monoclonal antibody inn a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995, 95:1897-1905.
17. Mendelsohn J, Fan Z: Epidermal growth factor receptor family and chemosensitization [editorial]. Natl Cancer Inst 1997, 89:341-343.
18. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53:4637-4642.
19. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J: Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993, 85:1327-1333.
20. Pegram MD, Pietras RJ, Slamon DJ: Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells [abstract 2639]. Proc Am Assoc Cancer Res 1992, 33:442.
21. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9:1829-1838.
22. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC: Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996, 13:1359-1365.
23. neu expressing non-small cell lung cancer cells. Cancer Res 1996, 56:1068-1074.
24. Pegram M, Lipton A, Pietras R, Hayes D, Weber B, Baselga J, Tripathy D, Twadell T, Glaspy J, Slamon D: Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1995, 14:A124.
25. Slovin SF, Kelley WK, Cohen R, Cooper M, Malone T, Weingard K, Waksal H, Falcey J, Mendelsohn J, Scher HI: Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): results of a phase Ib/IIa study [abstract 1108]. Proc Am Soc Clin Oncol 1997, 16:311a.
26. Falcey J, Pfister D, Cohen R, Cooper M, Bowden C, Burtness B, Mendelsohn J, Waksal H: A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas [abstract 1364]. Proc Am Soc Clin Oncol 1997, 16:383a.
27. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996, 88:1770-1776.
28. Sepp-Lorenzino L, Bos M, Ma Z, Baselga J, Rands E, Kohl NE, Oliff A, Mendelsohn J, Rosen N: Farnesyle: protein transferase inhibitors (FTIs) block tyrosine kinase signal transduction and act in concert with an anti-EGF receptor antibody to inhibit cancer cell growth [abstract 2877]. Proc Am Assoc Cancer Res 1996, 37:421.
29. Deshane J, Grim J, Loechel S, Siegal GP, Alvarez RD, Curiel DT: Intracellular antibody against erbB-2 mediated targeted tumor cell eradication by apoptosls. Cancer Gene Ther 1996, 3:89-98.
30. Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G, Liu T, Kay M, Curiel DT: Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 1996, 96:2980-2985.
31. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT: Intracellular single-chain antibody directed against erbB-2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1994, 1:332-337.
32. Beerli RR, Wels W, Hynes NE: Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994, 269:23931-23936.
33. Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE: Intracellular expression of a single-chain antibody directed to the EGF receptor leads to growth inhibition of tumor cells. Oncogene 1996, 13:275-282.
34. Beerli RR, Wels W, Hynes NE: Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophys Res Commun 1994, 204:666-672.
35. Featherstone C: Bispecific antibodies: the new magic bullets. Lancet 1996, 348:536.
36. Negri DRM, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and antitumor efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer 1995, 72:928-933.
37. Knuth A, Bernhard H, Jager E, Wolfel T, Karbach J, Jaggle C, Strittmatter W, Meyer zum Buschenfelde KH: Induction of tumor cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3. Eur J Cancer 1994, 8:1103-1107.
38. Morelli D, Sardini A, Villa E, Villa ML, Menard S, Colnaghi MI, Balsari A: Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. Cancer Immunol Immunother 1994, 38:171-177.
39. Zhu Z, Lewis GD, Carter P: Engineering high affinity humanized anti-p185/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER-2 overexpressing tumor cells. Int J Cancer 1995, 62:319-324.
40. Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C: Bispecific HER-2/CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER-2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol 1995, 74:185-192.
41. Stockmeyer B, Valerius T, Repp R, Heijnen IAFM, Buhring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JGJ: Preclinical studies with FcrγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophil as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997, 57:696-701.
42. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Ernstoff MS, Wells W, Barth R, Deo Y, Fisher J, et al.: Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematother 1995, 4:471-475.
43. Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, van de Winkel JG, Lang N, et al.: G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). J Hematother 1995, 4:415-421.
44. Weiner LM, Alpaugh RK, Amoroso AR, Adams GP, Ring DB, Barth MW: Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human FcγRIII. Cancer Immunol Immunother 1996, 42:141-150.
45. Weiner LM, Clark JI, Ring DB, Alpaugh RK: Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 1995, 4:453-456.
46. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK: Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res 1995, 55:4586-4593.
47. Deo YM, Granziano RF, Repp R, van de Winkel JG: Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 1997, 18:127-135.
48. Goldstein J, Graziano RF, Sundarapandiyan K, Somasundaram C, Deo YM: Cytolytic and cytostatic properties of an anti-human FcγRI (CD64) x epidermal growth factor bispecific fusion protein. J Immunol 1997, 158:872-879.
49. Wels W, Groner B, Hynes NE: Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Curr Top Microbiol Immunol 1996, 213:113-128.
50. Becker JC, Pancock JD, Gillies SD, Mendelsohn J, Reisfeld RA: Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A 1996, 93:2702-2707.
51. Reisfeld RA, Gillies SD, Mendelsohn J, Varki NM, Becker JC: Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphototoxin fusion protein. Cancer Res 1996, 56:707-1712.
52. Gerstmayer B, Altenschmidt U, Hoffmann M, Wels W: Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J Immunol 1997, 158:4584-4590.
53. Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE: EGF receptor and p185erbB2 specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 1995, 60:137-144.
54. Schmidt M, Wels W: Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGF-α. Br J Cancer 1996, 74:853-862.
55. Schmidt M, Hynes NE, Groner B, Wels W: A bivalent single-chain antibody-toxin specific for ErbB2 and the EGF receptor. Int J Cancer 1996, 65:538-546.
56. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I: Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phase display. Proc Natl Acad Sci U S A 1996, 93:14815-14820.
57. Cristiano R, Roth JA: Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 1996, 3:4-10.
58. Shimizu N, Chen J, Gamou S, Takayanagi A: Immunogene approach toward cancer therapy using erythrocyte growth factor receptor-mediated gene delivery. Cancer Gene Ther 1996, 3:113-120.